| INTRODUC TI ON
Duchenne muscular dystrophy (DMD; OMIM 310200) is a severe Xlinked recessive muscle disease affecting more than 1 in 5000 male births. 1 The major clinical manifestation of DMD is muscle weakness, which is present from childhood and progresses with age. Affected boys typically loss ambulation in their early teens and died from heart or respiratory failure in their 30 s. 2 DMD is caused by mutations in the DMD gene that disrupt the reading frame of the gene transcript. A milder and less common type of muscular dystrophy, Becker muscular dystrophy (OMIM 300376), is caused by mutations in the same gene that preserves the reading frame. 3 DMD gene is extremely large, over 2.2 Mb in size, with 79 exons that are interrupted by large introns. 4 More than 60% of identified DMD mutations are large deletions that span one to multiple exons. Duplications of one to multiple exons are less common, only accounting for 5%-10% of all cases. Point mutations and small insertions/deletions are considered the causative mutations for the remaining cases. 5, 6 Although the identification of disease-causing mutations in DMD is complicated by the 79 exons and a heterogeneous mutation spectrum, precise genetic diagnosis is required for the confirmation of clinical diagnosis, genetic counseling, and future treatment with mutation-specific therapy. 7, 8 Many screening methods are available to detect large deletions, including multiplex PCR that was initially developed to selectively amplify 19 exons at deletion hotspots in two reactions. 9, 10 This simple method identifies more than 95% of deletions, so has been widely used. 11 However, additional analysis is required to define the deletion end and obtain a precise deletion diagnosis. Additionally, multiplex PCR is not suitable for checking the female carrier status. Multiplex ligationdependent probe amplification (MLPA) is a semiquantitative method that has been developed since multiplex PCR. 12 MLPA involves the PCR amplification of probes that hybridize to exonic sequences, allowing the relative quantification of all 79 DMD exons in both patients and carriers. 13 MLPA has become the standard method for detecting not only large deletions but also duplications, which has significantly improved the molecular diagnosis of DMD. 6, 14 More recently, next-generation sequencing (NGS), the high-throughput DNA sequencing technology, has been used for the genetic diagnosis of DMD. Targeted NGS of DMD as a single gene or within a gene panel has been developed, offering a single platform to detect a broad mutational spectrum from small mutations to large rearrangements including exon deletions and duplications. [15] [16] [17] In a mutation study of a Chinese patient with DMD, we observed a discrepant amplification of DMD exon 43 between multiplex PCR and MLPA. Using the benefits of targeted NGS, we were able to identify a novel partial exonic deletion as the cause of the discrepancy.
| MATERIAL S AND ME THODS

| Patient
The patient was a 14-year-old Chinese boy who was born to healthy parents with no family history of muscular disorders. He started to walk at the age of 1.5 years, but slowness when climbing the stairs was noted at the age of 4. 
| Multiplex PCR
In the patient's previous genetic test, the traditional two sets of multiplex PCR primers were used to amplify 19 DMD exons that commonly carry deletions in DMD. 9, 10 The amplified PCR products were separated on a 3% agarose gel and visualized by ethidium bromide staining.
| MLPA analysis
The SALSA MLPA KIT P034/P035 for DMD was purchased from MRC-Holland (Amsterdam, the Netherlands) and used according to the manufacturer's instructions.
| Targeted NGS analysis
Targeted NGS for DMD was conducted by MyGenostics Inc. (Beijing, China). Briefly, a genomic DNA library of the index patient was constructed and hybridized with biotinylated DNA probes to capture nearly 2.1 Mb of the entire genomic region of DMD gene (UCSC hg19
corresponding to chrX:31137345-33357726, NC_000023.10, NCBI build 37). The captured DNA was then selected by streptavidincoated magnetic beads, PCR-amplified, and sequenced on an Illumina Hiseq2000 sequencer (San Diego, CA, USA). Sequenced data were processed using bcl2fastq Conversion Software 2.18.0.12 (Illumina Inc., CA, USA) for base calling and clean data. Low-quality variations were filtered out using a quality score ≥20. Burrows-Wheeler
Aligner software was then used to align the clean reads to the reference human genome (hg19), producing a BAM file. Deletions were detected by read depth estimation. The rough breakpoint can be seen in the Integrative Genomics Viewer. The relevant consensus sequence in the SV file was then aligned to hg19 to obtain an accurate sequence.
The detailed experimental protocol has been described elsewhere. 
| Validation of the breakpoint by PCR amplification and Sanger sequencing
The junction sequence detected by NGS in the index patient was further confirmed by conventional PCR using a forward primer located in intron 42 (5′-AGAATTGCAAC ACCATTTGCTACC-3′) and a reverse primer in intron 43
(5′-TCAACGGTCCTTAGGGGATG-3′). PCR products were purified and subjected to Sanger sequencing. The nucleotide position was based on the reference sequence from NCBI for Dp427 m (NM_004006.2), with +1 representing the A of the ATG translational initiation codon.
| RE SULTS
| Discrepancy between multiplex PCR and MLPA analysis
The index patient had previously undergone genetic testing. At this time, traditional multiplex PCR failed to detect an amplified product corresponding to DMD exon 43, indicating a deletion of this exon Figure 1A ). However, because this method does not cover every DMD exon, the extent of the deletion had not been fully defined.
To obtain a precise genetic diagnosis for the index patient and 
| Targeted NGS disclosed a deletion mutation in the patient with DMD
To clarify the genetic diagnosis, we further examined the patient's DMD gene, including the introns, using targeted NGS. The sequence coverage and depth for the patient sample are summarized in Table 1 . By carefully analyzing the sequencing data surrounding exon 43 and its flanking introns, the absence of sequence reads between chrX: 32304536-32305695 (NC_000023.10) corresponding to c.6241_c.6290 + 1109 (NM_004006.2) in the DMD gene was identified ( Figure 1C ), indicating the presence of a deletion mutation in the patient.
| Confirmation of the deletion breakpoint
The deletion junction was further confirmed by conventional PCR using primers flanking the deletion breakpoint suggested by tar- In the patient's DMD gene, an AC dinucleotide was inserted at the deletion breakpoint. B, PCR amplification of the deletion junction using a forward primer in intron 42 (arrow in Figure 2A ) and a reverse primer in intron 43 (arrowhead in Figure 2A To determine the carrier status of the patient's sister, her genomic DNA was examined for the presence of the deletion junction by conventional PCR. Only a PCR product of normal size was obtained, which excluded the possibility of her being a carrier (data not shown).
| D ISCUSS I ON
Multiplex PCR and MLPA have been widely used for mutation detection in DMD cases. amplification, leading to its apparent loss ( Figure 1A) . Conversely, in MLPA testing, the probe recognition sites were retained so exon 43 was amplified, causing the partial deletion to completely escape MLPA detection ( Figure 1B ). Although MLPA has been accepted as a reliable method for detecting copy number variations, its limited probe coverage on target regions could cause it to miss mutations. 20 In fact, MLPA failed to detect some gross rearrangements in the α-galactosidase gene in patients with Fabry disease. 21 However, little was known about its problems in DMD mutation detection, and our
results are the first to show that MLPA can miss some partial exonic deletions in DMD.
Although the difference between partial and complete dele- showed the efficiency of targeted NGS in the detection of partial deletions.
The identification of a novel partial exon deletion of exon 43 further broadens the DMD mutational spectrum. Compared with a previous study that only analyzed DMD exons and 10 bp flanking introns, 16 our study performed targeted sequencing of the full-length DMD including entire introns. This led to the retrieval of a junction sequence, which provides the first insight into the molecular mechanism of partial exonic deletions in DMD.
In conclusion, we report the discrepant amplification of DMD exon 43 between multiplex PCR and MLPA in a Chinese patient. Validation by targeted NGS disclosed that the discrepancy was caused by a novel partial exonic deletion that escaped MLPA detection. Our results demonstrate the pitfalls of conventional screening methods in the accurate detection of partial deletions and demonstrate the power of targeted NGS in identifying unexpected DNA changes.
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